Galvanize Therapeutics Inc, a commercial-stage medical technology company focused on pulsed electric field (PEF) therapies for oncology and chronic lung disease, announced on Tuesday the completion of the first commercial procedures using its recently FDA-cleared Aliya EX System.

According to the company, this milestone marks the first clinical use of the Aliya EX System following its US FDA 510(k) clearance in May 2026 and the first commercial procedures across the Aliya PEF platform's two primary delivery pathways: percutaneous delivery and endoscopic delivery.

The first percutaneous procedure was performed by Joseph Mammarapallil, M.D., associate professor of Radiology at Duke University School of Medicine, and the first endoscopic procedure was performed by Justin Thomas, M.D., director of Interventional Pulmonology at Eisenhower Health.

Galvanize Therapeutics says that Aliya EX expands the capability of the Aliya PEF platform by delivering up to 2x larger ablation diameter, resulting in as much as a 7x increase in ablation volume, while maintaining the defining attributes of Aliya PEF. The system delivers electrical pulses that induce non-thermal regulated cell death, preserving surrounding tissue architecture and remaining compatible with existing oncologic diagnostic workflows and standard therapies.